Ulinastatin API is incorporated into sterile lyophilized vials at manufacturing sites where the lyophilization cycle is designed around the thermal sensitivity of a glycoprotein rather than small-molecule APIs. The filtered bulk solution is compounded in Water for Injection with mannitol as bulking agent and a sodium phosphate buffer; the protein concentration is adjusted to a unit dose so that reconstitution with 2 mL diluent yields a clear to slightly opalescent solution. The solution is passed through a 0.45 µm polyethersulfone prefilter and a 0.22 µm final membrane filter, with the filter train validated for bacterial retention under ASTM F838-20 and integrity tested by pre-use bubble point or diffusion flow. Filling is performed in Grade A laminar-airflow isolators into depyrogenated Type I borosilicate glass vials, followed by partial stoppering with chlorobutyl elastomer stoppers. The lyophilization cycle must hold the product below collapse temperature; for mannitol-containing formulations, annealing at -20°C to -15°C is commonly used to crystallize the bulking agent before primary drying, and shelf temperatures during primary drying are maintained below the glass transition of the maximally freeze-concentrated amorphous phase. Residual moisture is determined by coulometric Karl Fischer titration according to USP <921>, with release limits usually set between 1.0% and 3.0% w/w for lyophilized biological preparations. Batch-to-batch variance in cake appearance at production scale is frequently traced to uncontrolled nucleation during freezing, which can be reduced by controlled nucleation systems or annealing steps. The finished vials undergo sterility testing per USP <71>, bacterial endotoxin testing per USP <85> with a limit consistent with the administered dose, and subvisible particulate matter testing per USP <787>. The process operates under current good manufacturing practice as described in 21 CFR 210 and 21 CFR 211, with aseptic processing validation following ISO 13408-1.

Reconstitution at the point of use returns the lyophilized cake to a parenteral solution whose handling and storage differ from ready-to-use small-molecule injections. The diluent is typically physiological saline or a dedicated aqueous vehicle supplied with the vial; after reconstitution, the solution must be inspected for visible particulates and should be administered without delay unless product-specific in-use stability has been demonstrated. Commercial lyophilized presentations of ulinastatin in Japan are commonly labeled at 100,000 units per vial, and the reconstituted volume of 2 mL yields a defined unit concentration for subsequent dosing. The terminal finished product is a sterile, freeze-dried plug or cake that retains enzyme inhibitory activity only when the container closure system remains intact and the product is stored under labeled cold-chain conditions.

What Limits Diluted In-Use Stability in PVC Infusion Bags?

In diluted admixtures prepared from reconstituted ulinastatin solution, polyvinyl chloride infusion bags introduce adsorption and chemical stability constraints that are distinct from small-molecule parenterals. The reconstituted solution is typically transferred into 0.9% sodium chloride injection or 5% glucose injection; the choice of diluent must be based on site-validated in-use stability data because protein aggregation and subvisible particle counts can increase over time under pH and ionic strength changes. Polyvinyl chloride bags containing di(2-ethylhexyl) phthalate are often replaced by DEHP-free polyolefin or ethylene-vinyl acetate multilayer bags to reduce extractables interactions with the glycoprotein; the same rationale applies to infusion tubing. In hospital pharmacies, sterile compounding of ulinastatin admixtures is performed in ISO Class 5 laminar-airflow workbenches under USP <797> conditions, with a beyond-use date assigned only after site-specific stability verification. Published in-use stability data for ulinastatin diluted admixtures are limited; therefore, refrigerated storage at 2–8°C and administration within 24 h are conservative operational controls that many hospital pharmacies adopt unless the manufacturer provides longer validated data. The infusion rate for acute pancreatitis protocols is generally controlled by infusion pump because rapid administration of a high-unit dose may produce a transient viscosity-related line pressure increase in microbore tubing. Subvisible particulate testing by light obscuration under USP <787> or Ph. Eur. 2.9.19 should be performed on admixtures during stability evaluation, with particular attention to silicone oil droplets originating from disposable syringes and needle hubs. No terminal filtration of the infusion admixture is generally applied at the bedside because a final in-line filter may remove particulate load but also introduces protein adsorption; filtration decisions require product-specific compatibility testing. If the admixture is prepared in an automated compounding device, the pump cassette and transfer set materials must be screened for leachables and for loss of enzyme inhibitory activity over the holding period.

Sterile Filtration Cascades and Terminal Sterilization Boundaries

Because terminal steam sterilization is incompatible with the glycoprotein structure, manufacture of a parenteral ulinastatin product relies on aseptic filtration as the critical sterilizing step. The filtration cascade is designed with a 0.45 µm clarifying prefilter followed by a 0.22 µm sterilizing-grade membrane filter. Filter selection must address membrane chemistry: polyethersulfone and polyvinylidene fluoride membranes are commonly used, but filter binding studies with the specific protein concentration and formulation vehicle are required because low ionic strength phosphate buffers can increase electrostatic adsorption. Pre-use integrity testing is conducted on each filter assembly by bubble point, pressure hold, or diffusion flow according to manufacturer validated limits; post-use integrity testing detects process-related membrane damage from high viscosity or aggregate load. The maximum batch filtration time is governed by bioburden control before filtration and by protein aggregation kinetics in the hold vessel; bulk solution is maintained at 2–8°C and processed within validated hold times. A production-scale bottleneck occurs when membrane fouling reduces flux late in a batch, which may be minimized by using two parallel sterilizing filters or by selecting an upstream clarification step such as depth filtration or centrifugation. The filtrate is filled aseptically into vials, and filtration validation must demonstrate that the filter retains Brevundimonas diminuta at a challenge level not less than 10⁷ CFU/cm² under ASTM F838-20 conditions. The absence of terminal sterilization shifts the sterility assurance burden to aseptic process simulation with growth media, as described in ISO 13408-1, and to environmental monitoring of Grade A zones. Because ulinastatin is a glycoprotein, shear generated by peristaltic pumps or high-velocity filtration can produce subvisible aggregates that are not fully removed by the final filter; the filling line should therefore use low-shear pumps and minimize turbulent flow through sanitary piping.

For oral tablet and capsule development, Ulinastatin API is constrained by gastric proteolysis and luminal degradation because the molecule is a glycoprotein with a molecular mass near 30,000 Da and is inactivated by pepsin and pancreatic proteases. Systemic oral bioavailability is therefore expected to be negligible; published oral pharmacokinetic data for ulinastatin are limited, and commercial oral products are not established. If the API is processed into enteric-coated capsules, tablets, or granules for local intestinal enzyme inhibition, the formulation strategy must separate the protein from gastric fluid until the dosage form reaches the lower duodenum or upper jejunum. Enteric coating polymers such as methacrylic acid-methyl methacrylate copolymer dispersion, hydroxypropyl methylcellulose acetate succinate, or hypromellose phthalate are applied to either hard gelatin capsules or compressed tablet cores; the coating thickness must be high enough to resist acid infiltration but low enough to avoid cracking during pan coating or fluid-bed coating. For granules, a top-spray fluid-bed granulator can be used to agglomerate a lactose-mannitol filler mixture with a low-concentration binder solution, but wet granulation introduces heat and moisture that may reduce enzyme inhibitory activity; dry processing by roller compaction is preferred when the API is moisture-sensitive. The resulting granules or tablet cores require a protective seal coat before enteric coating, and the finished dosage form is tested for acid resistance in 0.1 N hydrochloric acid for 2 h followed by dissolution at pH 6.8 phosphate buffer according to compendial delayed-release methods. Moisture barrier packaging is required if the solid dosage form contains the glycoprotein, with desiccant loading calculated from water vapor transmission rate and package headspace volume. The operational boundary for solid oral processing is narrow: at ambient relative humidity above 60%, the API may hydrate and become sticky during milling or compression, so production suites are conditioned to 30–50% RH. Because oral tissue distribution and systemic absorption are not the primary objective for locally acting enteric-coated formulations, clinical development would need to specify luminal activity markers rather than plasma concentration; published data for this specific configuration is limited.

When Ulinastatin Injection Is Compounded into Multi-Dose Infusion Protocols in Critical Care

Critical care pharmacy workflows transfer the contents of a lyophilized vial into a carrier fluid at defined unit strengths for continuous or intermittent intravenous infusion. The starting presentation is often 100,000 units per vial, reconstituted to 2 mL, then diluted further to a final volume consistent with the prescribed dose per kilogram or per patient; dosing protocols for acute pancreatitis and disseminated intravascular coagulation generally use repeated bolus or short infusion schedules rather than prolonged continuous infusion. The compounding operator must record the total units transferred, the final diluent volume, and the beyond-use date on the label under USP <797> requirements, and must avoid using damaged vials with cracked lyophilized cakes because altered cake structure may indicate moisture ingress or loss of vacuum. In the critical care setting, the admixture is usually administered through a dedicated peripheral or central line; published compatibility data for simultaneous co-infusion with amino acid solutions, lipid emulsions, or other protease inhibitors are limited, and co-administration through the same lumen without site-specific verification is not recommended. The infusion line should be primed with diluent rather than the protein-containing admixture to minimize protein exposure to air interfaces and silicone oil. Flow rate selection is based on clinical protocol and is controlled by syringe pump or volumetric infusion pump; because the diluted solution has low viscosity, no measurable line pressure difference occurs at typical infusion rates below 250 mL/h. Temperature excursion during transport from the pharmacy to the intensive care unit should be minimized, with cold-chain transfer containers validated for 2–8°C if the beyond-use date exceeds immediate administration. The prepared admixture is inspected for visible particulates prior to hanging, and any evidence of cloudiness, precipitation, or phase separation triggers rejection because these changes may indicate protein aggregation or pH incompatibility with the carrier fluid.

Container Closure Integrity and Moisture Barrier Constraints for Freeze-Dried Units

Because the lyophilized cake in a Type I borosilicate glass vial remains moisture-sensitive after freeze-drying, container closure integrity is the controlling variable for shelf-life and sterility maintenance. Residual seal force is measured on production samples to ensure the elastomer closure maintains compression after capping; excessively low residual seal force can allow moisture ingress along the stopper flange, while excessively high residual seal force can deform the elastomer and create microchannels. Container closure integrity testing for lyophilized protein products is performed by helium leak, vacuum decay, or laser-based headspace gas analysis under USP <1207>; dye ingress is used as a destructive supplementary method but has lower sensitivity than vacuum decay for small breaches. After freeze-drying, the chamber is backfilled with nitrogen to reduce residual oxygen, and the headspace oxygen content is monitored by frequency-modulation spectroscopy on a sampling basis. The package insert and carton are designed to protect against light exposure because the glycoprotein and buffer components can undergo photo-oxidation; the carton should include a desiccant only when the primary container closure integrity has been validated, because desiccants remove headspace moisture but cannot correct a poor seal. Storage conditions for commercial lyophilized ulinastatin presentations are specified in the approved labeling; typical cold-chain storage at 2–8°C or below 15°C is used depending on market authorization. Temperature excursions above the labeled storage condition during distribution require stability data that include enzyme inhibitory activity assay, high-molecular-weight aggregate content by size-exclusion chromatography, and subvisible particle counts. At the hospital receiving stage, vials with puckered or lifted stoppers, missing overseals, or cracked glass are rejected before compounding because container closure integrity can no longer be assured.